There are currently 581 clinical trials in Denver, Colorado looking for participants to engage in research studies. Trials are conducted at various facilities, including Porter Adventist Hospital, National Jewish Health, Rose Medical Center and Colorado Blood Cancer Institute. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors
NCT06065059
Recruiting
The goal of this interventional clinical trial is to learn about TNG348, a ubiquitin specific peptidase 1 (USP1) inhibitor, alone and in combination with olaparib in patients with BRCA 1/2 mutant or HRD+ solid tumors. The main question[s] it aims to answer are: to evaluate the safety and tolerability of single agent and combination therapy to determine the recommended dose for Phase 2 of single agent and combination therapy to determine the pharmacokinetics of TNG348 as a single agent and in c... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/27/2024
Locations: HealthONE, Denver, Colorado
Conditions: Breast Cancer, Ovarian Cancer, Pancreas Cancer, Prostate Cancer, BRCA1 Mutation, BRCA-Mutated Ovarian Carcinoma, BRCA-Associated Breast Carcinoma, HRD Positive Advanced Ovarian Cancer
Register for Updates
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
NCT03866382
Recruiting
This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that that has spread from where it first started (primary site) to other places in the body. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfer... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/27/2024
Locations: Porter Adventist Hospital, Denver, Colorado
Conditions: Bladder Adenocarcinoma, Bladder Mixed Adenocarcinoma, Bladder Squamous Cell Carcinoma, Chromophobe Renal Cell Carcinoma, Kidney Medullary Carcinoma, Large Cell Neuroendocrine Carcinoma, Metastatic Bladder Carcinoma, Metastatic Bladder Large Cell Neuroendocrine Carcinoma, Metastatic Bladder Squamous Cell Carcinoma, Metastatic Kidney Medullary Carcinoma, Metastatic Malignant Genitourinary System Neoplasm, Metastatic Penile Carcinoma, Metastatic Sarcomatoid Renal Cell Carcinoma, Papillary Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma, Stage IV Bladder Cancer AJCC v8, Stage IV Penile Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8, Bladder Clear Cell Adenocarcinoma, Bladder Neuroendocrine Carcinoma, Collecting Duct Carcinoma, Metastatic Urethral Carcinoma, Stage IV Urethral Cancer AJCC v8, Urethral Clear Cell Adenocarcinoma, Bladder Small Cell Neuroendocrine Carcinoma, Metastatic Bladder Small Cell Neuroendocrine Carcinoma, Metastatic Prostate Small Cell Neuroendocrine Carcinoma, Invasive Bladder Giant Cell Urothelial Carcinoma, Invasive Bladder Lymphoepithelioma-Like Carcinoma, Invasive Bladder Nested Urothelial Carcinoma, Invasive Bladder Plasmacytoid Urothelial Carcinoma, Invasive Bladder Sarcomatoid Urothelial Carcinoma, Invasive Bladder Urothelial Carcinoma, Metastatic Bladder Clear Cell (Glycogen-Rich) Urothelial Carcinoma, Metastatic Bladder Lipid-Rich Urothelial Carcinoma, Metastatic Bladder Micropapillary Urothelial Carcinoma, Metastatic Bladder Plasmacytoid Urothelial Carcinoma, Metastatic Bladder Sarcomatoid Urothelial Carcinoma, Urachal Adenocarcinoma, Malignant Testicular Leydig Cell Tumor, Malignant Testicular Sertoli Cell Tumor, Metastatic Bladder Giant Cell Urothelial Carcinoma, Metastatic Chromophobe Renal Cell Carcinoma, Metastatic Papillary Renal Cell Carcinoma
Register for Updates
Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma
NCT04204941
Recruiting
The participants of this study will have advanced epithelioid sarcoma. Sarcoma is a cancer of the connective tissues, such as nerves, muscles and bones. Epithelioid sarcoma is an ultra-rare sarcoma of the soft-tissue. Part 1 of this trial will evaluate the safety and the level of the study drug that the study drug combinations can be tolerated (known as tolerability). It is also designed to establish a recommended study drug dosage for the next part of the study. Part 2 will evaluate and compa... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/26/2024
Locations: Sarah Cannon Research Institute at HealthONE, Denver, Colorado
Conditions: Advanced Epithelioid Sarcoma, Advanced Soft-tissue Sarcoma
Register for Updates
A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma (VATHOS)
NCT05202262
Recruiting
This is a 24 week study to evaluate the efficacy and safety of budesonide and formoterol fumarate metered dose inhaler in adults and adolescents with inadequately controlled asthma.
Gender:
All
Ages:
Between 12 years and 80 years
Trial Updated:
04/26/2024
Locations: Research Site, Denver, Colorado
Conditions: Asthma
Register for Updates
Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation
NCT05609578
Recruiting
Study 849-017 is an open-label, Phase 2 clinical trial evaluating the clinical efficacy of adagrasib in combination with pembrolizumab and chemotherapy in the first-line setting for patients with advanced NSCLC with TPS ≥ 1%, TPS <50% and KRAS G12C mutation
Gender:
All
Ages:
18 years and above
Trial Updated:
04/26/2024
Locations: USOR - Rocky Mountain Cancer Centers - Denver - Rose Medical Center Campus, Denver, Colorado
Conditions: Advanced NSCLC, Metastatic Lung Cancer
Register for Updates
A Phase 2 Proof of Concept Study to Evaluate the Efficacy and Safety of Daxdilimab in Participants With Dermatomyositis (DM) or Anti-synthetase Inflammatory Myositis (ASIM)
NCT05669014
Recruiting
The primary efficacy objective: To evaluate the effect of daxdilimab compared with placebo in reducing disease activity at Week 24. The secondary efficacy objectives include: To evaluate the effect of daxdilimab compared with placebo in reducing disease activity at Week 24. To evaluate the effect of daxdilimab compared with placebo on skin symptoms at Week 24. To evaluate the effect of daxdilimab on decreasing the use of corticosteroid at Week 24. Other secondary objectives include: To char... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
04/26/2024
Locations: National Jewish Health, Denver, Colorado
Conditions: Idiopathic Inflammatory Myositis
Register for Updates
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
NCT03435796
Recruiting
This is a prospective study for the long-term follow-up (LTFU) of safety and efficacy for all pediatric and adult participants exposed to Gene-modified (GM) T cell therapy participating in a previous Celgene sponsored or Celgene alliance partner sponsored study. Participants who received at least one GM T cell infusion will be asked to enroll in this LTFU protocol upon either premature discontinuation from, or completion of the prior parent treatment protocol.
Gender:
All
Ages:
All
Trial Updated:
04/26/2024
Locations: Colorado Blood Cancer Institute, Denver, Colorado
Conditions: Neoplasms
Register for Updates
An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib
NCT05513001
Recruiting
The purpose of this extension study is to collect long-term efficacy, safety and tolerability data on remibrutinib in a selected group of participants with Chronic Spontaneous Urticaria (CSU) who previously completed the treatment phase of remibrutinib preceding Phase 3 studies. This study will also fulfill the Novartis commitment to provide post-trial access to participants who have completed the preceding Phase 3 studies, where applicable.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/26/2024
Locations: Colorado Allergy and Asthma Ctr PC ., Denver, Colorado
Conditions: Chronic Spontaneous Urticaria
Register for Updates
A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)
NCT05617677
Recruiting
The purpose of this study is to evaluate the effectiveness and safety of deucravacitinib compared with placebo in an active moderate to severe Systemic Lupus Erythematosus (SLE) population.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
04/25/2024
Locations: Denver Arthritis Clinic, Denver, Colorado
Conditions: Systemic Lupus Erythematosus
Register for Updates
Longitudinal Study for Eosinophilic Granulomatosis With Polyangiitis
NCT00315380
Recruiting
Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare immune system disorder that causes asthma, an excessive number of eosinophils (a type of white blood cell) in the blood, and the inflammation of blood vessels, or vasculitis. In order to properly treat EGPA, it is critical that the level of disease activity can be determined over the course of the disease. The purpose of this study is to determine new biological markers, or biomarkers, that may be used to assess the severity of this... Read More
Gender:
All
Ages:
All
Trial Updated:
04/25/2024
Locations: National Jewish Health, Denver, Colorado
Conditions: Eosinophilic Granulomatosis With Polyangiitis, Churg-Strauss Syndrome
Register for Updates
Phase 2a Study to Assess the Efficacy and Safety of AZD4604 in Adult Patients With Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA
NCT06020014
Recruiting
This is a Phase 2a, multicentre, randomised, placebo-controlled, double-blind, parallel-group study to evaluate the efficacy, safety and PK of AZD4604 administered BID using a dry-powder inhaler at one dose level over a 12-week Treatment period in adult participants with uncontrolled moderate-to-severe asthma.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
04/25/2024
Locations: Research Site, Denver, Colorado
Conditions: Asthma
Register for Updates
A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT04910568
Recruiting
This Phase Ib, multicenter, open-label study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of cevostamab monotherapy, cevostamab plus pomalidomide and dexamethasone (Pd) or cevostamab plus daratumumab and dexamethasone (Dd) which will be administered to participants with relapsed or refractory multiple myeloma (R/R MM) via intravenous (IV) infusion.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/25/2024
Locations: Colorado Blood Cancer Institute (CBCI) at Presbyterian/ St. Luke's Medical Center, Denver, Colorado
Conditions: Multiple Myeloma
Register for Updates